CIK 0001599298 · Large accelerated filer
Summit Therapeutics Inc.
Sign in to watch- Ticker
- SMMT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 371979717
- Phone
- 305-203-2034
- Business address
- 601 BRICKELL KEY DRIVE, SUITE 1000, MIAMI, FL, 33131
- Former names
- Summit Therapeutics plc, Summit Corp plc
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Chief Executive Officer bought 5,000 shares at $2.07 ($10,350)
- 4 Open-market buy Chief Financial Officer bought 20,400 shares at an average $2.17 ($44,254)
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Chief Operating Officer bought 2,976,190 shares at $1.68 ($4,999,999)
- 4/A Open-market buy Co-CEO & President bought 23,527,044 shares at $1.05 ($24,703,396)
- 4 Open-market buy Co-Chief Executive Officer bought 23,527,044 shares at $1.05 ($24,703,396)
- 4 Open-market buy Chief Financial Officer bought 196,362 shares at $1.05 ($206,180)
- 4/A Open-market buy Chief Financial Officer bought 37,685 shares at $0.97 ($36,554)
- 4 Open-market buy Chief Executive Officer bought 376,489,880 shares at $1.05 ($395,314,374)
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 4 of 7 · 130 filings